{"DataElement":{"publicId":"6816088","version":"1","preferredName":"BRAF Gene Cytogenetic Abnormality Identification Type","preferredDefinition":"The response that indicates the type of BRAF aberration identified by genetic analysis","longName":"BRAF_Aberration_Type","context":"PBTC","contextVersion":"1","DataElementConcept":{"publicId":"6813141","version":"1","preferredName":"BRAF Gene Cytogenetic Abnormality Identification","preferredDefinition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis._An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material._The procedure of having an identity established.","longName":"3107133v1.0:6813139v1.0","context":"PBTC","contextVersion":"1","ObjectClass":{"publicId":"3107133","version":"1","preferredName":"BRAF Gene","preferredDefinition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","longName":"C18363","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF Gene","conceptCode":"C18363","definition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-1259-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-04","modifiedBy":"ONEDATA","dateModified":"2010-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6813139","version":"1","preferredName":"Cytogenetic Abnormality Identification","preferredDefinition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.:The procedure of having an identity established.","longName":"C2950:C25737","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identification","conceptCode":"C25737","definition":"The procedure of having an identity established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCB243C-A221-56E0-E053-F662850A9792","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435029","version":"1","preferredName":"Molecular Abnormality","preferredDefinition":"Abnormalities that occur in human cells and tissues and models of human cancer.","longName":"C3910","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432BB3-787B-25DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCB243C-A232-56E0-E053-F662850A9792","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"RICHARDS","dateModified":"2019-07-10","changeDescription":"slr for PBTC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6813142","version":"1","preferredName":"BRAF Aberration Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6813142v1.0","context":"PBTC","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"V600K","valueDescription":"BRAF NP_004324.2:p.V600K","ValueMeaning":{"publicId":"6061804","version":"1","preferredName":"BRAF NP_004324.2:p.V600K","longName":"6061804","preferredDefinition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by lysine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF NP_004324.2:p.V600K","conceptCode":"C98347","definition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by lysine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"648DAFC3-B46D-7875-E053-F662850A9289","latestVersionIndicator":"Yes","beginDate":"2018-02-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-06","modifiedBy":"ONEDATA","dateModified":"2018-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CCB4A5D-73FA-3A05-E053-F662850ACE47","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Specify Other","ValueMeaning":{"publicId":"6782229","version":"1","preferredName":"Specify Other","longName":"6782229","preferredDefinition":"A directive to indicate a response not listed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify Other","conceptCode":"C157106","definition":"A directive to indicate a response not listed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B4B4921-90A3-4044-E053-F662850ADEE5","latestVersionIndicator":"Yes","beginDate":"2019-06-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-14","modifiedBy":"TSESU","dateModified":"2022-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CCB4A5D-73DC-3A05-E053-F662850ACE47","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"V600E","valueDescription":"BRAF NP_004324.2:p.V600E","ValueMeaning":{"publicId":"3536308","version":"1","preferredName":"BRAF NP_004324.2:p.V600E","longName":"3536308","preferredDefinition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by glutamic acid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF NP_004324.2:p.V600E","conceptCode":"C98342","definition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by glutamic acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5D686D5-F5DC-76D9-E040-BB89AD433B31","latestVersionIndicator":"Yes","beginDate":"2012-07-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-27","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CCB4A5D-7404-3A05-E053-F662850ACE47","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"V600D","valueDescription":"BRAF NP_004324.2:p.V600D","ValueMeaning":{"publicId":"3540174","version":"1","preferredName":"BRAF NP_004324.2:p.V600D","longName":"3540174","preferredDefinition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by aspartic acid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF NP_004324.2:p.V600D","conceptCode":"C98340","definition":"A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by aspartic acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C64B7AB4-7525-3222-E040-BB89AD434936","latestVersionIndicator":"Yes","beginDate":"2012-08-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-02","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CCB4A5D-740E-3A05-E053-F662850ACE47","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"BRAF Rearrangement","valueDescription":"BRAF Gene DNA Sequence Rearrangement","ValueMeaning":{"publicId":"6816084","version":"1","preferredName":"BRAF Gene DNA Sequence Rearrangement","longName":"6816084","preferredDefinition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.: Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF Gene","conceptCode":"C18363","definition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"DNA Sequence Rearrangement","conceptCode":"C21069","definition":"Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D5C12E0-4685-5235-E053-F662850AF72D","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D5C12E0-469E-5235-E053-F662850AF72D","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435029","version":"1","preferredName":"Molecular Abnormality","preferredDefinition":"Abnormalities that occur in human cells and tissues and models of human cancer.","longName":"C3910","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432BB3-787B-25DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCB4A5D-73BD-3A05-E053-F662850ACE47","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-03","modifiedBy":"RICHARDS","dateModified":"2019-07-10","changeDescription":"slr for PBTC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"BRAF aberration identified:","type":"Preferred Question Text","description":"BRAF aberration identified:","url":null,"context":"PBTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D5C18E7-03E8-5239-E053-F662850A910C","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"RICHARDS","dateCreated":"2019-07-10","modifiedBy":"RICHARDS","dateModified":"2019-07-10","changeDescription":"PBTC 071019 slr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}